Eversept Partners, LP Protagonist Therapeutics, Inc Transaction History
Eversept Partners, LP
- $993 Million
- Q2 2025
A detailed history of Eversept Partners, LP transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Eversept Partners, LP holds 277,316 shares of PTGX stock, worth $15.1 Million. This represents 1.54% of its overall portfolio holdings.
Number of Shares
277,316
Previous 547,116
49.31%
Holding current value
$15.1 Million
Previous $26.5 Million
42.07%
% of portfolio
1.54%
Previous 2.93%
Shares
9 transactions
Others Institutions Holding PTGX
# of Institutions
295Shares Held
67.4MCall Options Held
290KPut Options Held
318K-
Farallon Capital Management LLC San Francisco, CA6.17MShares$337 Million1.53% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$314 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.76MShares$314 Million4.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.36MShares$238 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.25MShares$177 Million6.36% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.68B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...